85 + Investors. Track Smart Money conviction in XOVR. See who's accumulating, reducing, or initiating positions.
Based on 83 hedge funds · latest filing: 2025 Q4 · updated quarterly
Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.
No strong consensus or elite conviction detected among institutional holders.
Track Smart Money conviction in XOVR. See who's accumulating, reducing, or initiating positions.
| Metric | All 13F Filers (2025 Q4) | Prior (2025 Q3) | Change |
|---|---|---|---|
| Funds Holding | 85 | 73 | 16.44% |
| 13F Shares | 43M | 6M | 605.18% |
| Total Value | $869M | $129M | 573.83% |
| New Positions | 22 | 18 | +4 |
| Increased Positions | 35 | 29 | +6 |
| Closed Positions | 10 | 10 | - |
| Reduced Positions | 19 | 11 | +8 |
| Total Calls | 2 | 3 | -33.33% |
| Total Puts | 1 | 0 | 100% |
| PUT/CALL Ratio | 0.5 | 0.0 | Bullish |
| Market Cap | -- |
| Enterprise Value | -- |
| Trailing P/E | -- |
| Forward P/E | -- |
| PEG Ratio (5yr expected) | -- |
| Price/Sales (ttm) | -- |
| Price/Book (mrq) | -- |
| Enterprise Value/Revenue | -- |
| Enterprise Value/EBITDA | -- |
| Beta (5Y Monthly) | -- |
| Short Ratio (Days to Cover) | -- |
| Short % of Float | -- |
| Profit Margin | -- |
| Return on Assets (ttm) | -- |
| Return on Equity (ttm) | -- |
| Revenue (ttm) | -- |
| Net Income Avi to Common (ttm) | -- |
| Diluted EPS (ttm) | -- |
| Total Cash (mrq) | -- |
| Total Debt/Equity (mrq) | -- |
| Levered Free Cash Flow (ttm) | -- |
Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in XOVR. Verified SEC 13F-HR filings.
| Investor | Ownership History |
% of Portfolio | Prev % | Rank | Conviction | Avg Buy Price | 13F Score™ 3Y / 7Y | Sell Timing | Shares | Mkt Value | Change | Change % | Source | Quarter | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Buying streak — 6 quarters in a row: For 6 consecutive quarters, more hedge funds added XOVR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
More buyers than sellers — 67% buying: Last quarter: 56 funds were net buyers (22 opened a brand new position + 34 added to an existing one). Only 28 were sellers (18 trimmed + 10 sold completely). A clear majority buying is a strong confirmation signal.
Elite ownership — 42% AUM from top-100 funds: 9 of 83 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in XOVR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
Mostly new holders — 54% entered in last year: Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.
Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.